HRD Testing Solution
Oncology (Solid Tumors)
CommercialActive
Key Facts
About SeqOne Genomics
SeqOne Genomics has established itself as a key enabler of precision medicine by offering a comprehensive, cloud-based bioinformatics platform that transforms complex genomic data into clinically actionable insights. Its core value proposition lies in combining automation, AI-driven variant prioritization (DiagAI Score), and robust security with a flexible, pay-per-analysis business model, serving over 160 labs across 30+ countries. The company is strategically positioned at the intersection of the growing demand for genomic testing in oncology, rare diseases, and infectious diseases, and the need for labs to manage increasing data complexity efficiently and cost-effectively.
View full company profileTherapeutic Areas
Other Oncology (Solid Tumors) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-02 | Molecure | Phase I |
| ANXV | Annexin Pharmaceuticals | Preclinical |
| Athebody® DARPins for Targeted Radioligands (with POINT Biopharma) | Athebio | Pre-clinical |
| AB821 | Asher Biotherapeutics | Preclinical |
| VEGF Kinoid | Neovacs | Preclinical |
| Undisclosed Preclinical Pipeline | OncoResponse | Preclinical |
| Undisclosed Platform Program | Da Zen Theranostics | Pre-clinical |
| Compound42 | Abbmira Therapeutics | Pre-clinical |
| Clinical Decision Support Service | Curematch | Commercial |
| CV6-168 | CV6 Therapeutics | Phase 1a |
| Chemophototherapy (CPT) | POP Biotechnologies | Pre-clinical |
| Platform Validation & Partnership Development | SingleCell Biotechnology | Pre-clinical |